The Dermatology Digest

JULY 24, 2024

Stelara is a currently approved treatment for adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn’s, and moderately to severely active ulcerative colitis.

Dermatology 78

Dermatology Sales Marketing Safety 78

Dermatology Times

JANUARY 9, 2024

Experts in dermatology highlight the crucial role of setting treatment response expectations and stress the need for discussions on managing mild plaque psoriasis, highlighting the utilization of systemic therapies in this context.

Safety 77

Safety Education Therapy Management 77

Dermatology Times

NOVEMBER 5, 2024

As news of benzene contamination in benzoyl peroxide products continues to raise safety discussions, Steve Xu, MD, MSc, advocates for stricter regulations, increased research, and the consideration of safer acne treatment alternatives.

Treatments 73

Treatments Safety 73

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

The Dermatology Digest

NOVEMBER 20, 2024

Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx, UCB) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). Today’s approval of bimekizumab-bkzx is an exciting time for the hidradenitis suppurativa community, offering a new possibility for the treatment of people in the U.S.

Safety 78

Safety Sustainability Clinic Medical 78

Dermatology Times

MAY 13, 2024

5 experts share insights on long-term safety, efficacy, demographic variances, and more in pediatric AD.

Safety 74

Safety Treatments 74

Southeastern Esthetics Institute

AUGUST 23, 2016

Having a thorough understanding of the dermatology and plastic surgery procedures, in addition to all new and modern cosmetic procedures on the market, is critical in assisting your clients in answering questions. Having daily and weekly communication when dealing with patients receiving treatment is critical.

Esthetician 195

Esthetician Esthetics Document Office 195

Dermatology Times

DECEMBER 18, 2024

The new research identified notable improvements in disease severity, sweat reduction, and quality of life for patients treated with sofpironium.

Safety 64

Safety Treatments 64

Dermatology Times

JANUARY 9, 2024

Experts in dermatology emphasize the need to consider patients' overall well-being when evaluating the safety profiles of emerging biologic treatments for plaque psoriasis, taking into account the heightened levels of depression and anxiety in individuals with this condition.

Safety 36

Safety Treatments Dermatology 36

Alison Bladh

JANUARY 1, 2025

Lets dive into the causes of thinning brows and explore effective treatments that can help restore their shape, fullness, and confidence. Treatments to Restore and Enhance Eyebrows Thankfully, there are numerous options to address thinning eyebrows, from at-home remedies to professional treatments. Dermatologic Therapy.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). Zoryve foam was approved by the U.S.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

Dermatology Times

SEPTEMBER 12, 2023

Researchers compared the efficacy of the 2 modalities and found that they were equal in safety, efficacy, and tolerability.

Safety 83

Safety Treatments 83

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

Dermatology Times

DECEMBER 12, 2024

Karan Lal, DO, MS, FAAD, discusses how to balance safety and efficacy considerations while promoting treatment adherence in young vitiligo patients, focusing on the unique challenges and monitoring requirements for this vulnerable population.

Safety 36

Safety Treatments 36

Dermatology Times

NOVEMBER 25, 2024

The JAK inhibitor was significantly superior in all safety and efficacy endpoints, when compared to other AA treatment options.

Treatments 57

Treatments Safety 57

The Dermatology Digest

AUGUST 20, 2024

Food and Drug Administration (FDA) approved apremilast for the treatment of moderate to severe plaque psoriasis in children and adolescents ages 6 and older who weigh at least 20 kg (44 lb) and are candidates for phototherapy or systemic therapy. The adverse events were consistent with the known safety profile of Otezla in adult patients.

Safety 74

Safety Injections Therapy Treatments 74

Dermatology Times

AUGUST 8, 2024

Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.

Safety 36

Safety Treatments Therapy 36

Dermatology Times

JANUARY 8, 2024

Systemic corticosteroids are often used as primary therapy for PG, but alternatives should be considered for their favorable safety profile.

Clinic 78

Clinic Management Safety Treatments 78

The Dermatology Digest

JUNE 5, 2024

Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025. The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks.

Safety 73

Safety Office Facials Therapy 73

Dermatology Times

AUGUST 10, 2023

The treatments also led to a decrease in the density of immunohistochemistry of sweat glands.

Safety 68

Safety Treatments 68

Dermatology Times

JULY 4, 2024

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

Safety 36

Safety Therapy Treatments 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). The FDA has granted nemolizumab Priority Review for prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

Dermatology Times

JANUARY 13, 2025

A panelist discusses how advances in laser technology have improved safety protocols and treatment precision for patients across diverse skin tones, enabling more inclusive and effective cosmetic procedures.

Safety 36

Safety Skin Types Technology Treatments 36

Dermatology Times

AUGUST 23, 2023

Lakshi Aldredge, MSN, ANP-BC, comments on the implications of long-term safety data in patients who may not have responded to initial treatment of plaque psoriasis.

Safety 36

Safety Treatments 36

The Dermatology Digest

MARCH 18, 2024

Food and Drug Administration (FDA) has accepted Journey Medical’s New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024. “We

Rosacea 74

Rosacea Medical Office Clinic 74

Dermatology Times

JANUARY 2, 2025

The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.

Safety 36

Safety Dermatitis Management Clinic 36

Dermatology Times

MAY 13, 2024

They are confident prescribing roflumilast to patients with diverse skin and hair characteristics, including those with a history of hair treatments.

Safety 74

Safety Dermatitis Treatments 74

The Dermatology Digest

MAY 16, 2024

Sonelokimab is being assessed in two lead indications, HS and psoriatic arthritis (PSA), and the Company is pursuing other indications in dermatology and rheumatology. Sonelokimab is not yet approved for use in any indication. The Phase 3 VELA program is expected to enroll 800 patients across VELA-1 and VELA-2. HiSCR75 and beyond).

Safety 68

Safety Clinic Dermatology Office 68

The Dermatology Digest

SEPTEMBER 23, 2024

Delgocitinib, a topical pan-Janus kinase (JAK) inhibitor, is the first topical treatment to be specifically indicated for adult patients living with moderate to severe CHE across the European Union (EU) for whom topical corticosteroids are inadequate or inappropriate. Both trials met their primary and all secondary endpoints. In the U.S.,

Eczema 66

Eczema Safety Dermatology Clinic 66

The Dermatology Digest

MAY 17, 2024

Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed durable response rates and consistent safety in patients with moderate-to-severe plaque psoriasis after four years of continuous treatment, according to results from the POETYK PSO long-term extension (LTE) trial. patient-years (PYs) for the safety analyses. Year 4, 0.1)

Safety 36

Safety Sustainability Clinic Innovations 36

Dermatology Times

SEPTEMBER 6, 2023

Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, reviews the safety data of TYK2 inhibitors compared to other systemic agents in the same class.

Safety 36

Safety Treatments 36

The Dermatology Digest

APRIL 16, 2024

Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use as a biosimilar to Stelara for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. says Thomas Rainey, Senior Vice President, U.S.

Partnerships 74

Partnerships Injections Safety Marketing 74

The Dermatology Digest

OCTOBER 7, 2024

Several topical benzoyl peroxide (BPO) acne and rosacea treatments may contain too-high levels of benzene, according to new research in the Journal of Investigative Dermatology. Both of these studies are published in the Journal of the American Academy of Dermatology. What did the new study show? ” Richard L. .

Rosacea 74

Rosacea Safety Dermatology Branding 74

Dermatology Times

APRIL 12, 2024

Dr Linda Stein-Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the perception of limited treatment access and strategies for overcoming this barrier.

Safety 36

Safety Treatments 36

The Dermatology Digest

JANUARY 20, 2024

By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch. Evommune, Inc.

Safety 74

Safety Office Dermatitis Clinic 74

Dermatology Times

DECEMBER 5, 2024

Panelists discuss how current HS treatments, ranging from topical antibiotics to biologics, show varying degrees of efficacy in managing symptoms, while highlighting the need for individualized treatment approaches based on disease severity and patient factors.

Safety 36

Safety Treatments Management 36

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 80

Retinol Social Media Skincare Routine Skincare 80